Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Opioid agonist and antagonist behavioural effects of buprenorphine

View through CrossRef
The agonist and antagonist effects of a range of bupenorphine doses (0.08–20 mg/kg) were studied on the responding of pigeons under a multiple fixed‐ratio, fixed‐interval schedule of grain presentation. Various doses (0.02–10 mg/kg) of buprenorphine were also tested in pigeons trained to discriminate between injections of 0.05 mg/kg of fentanyl and injections of distilled water. Buprenorphine, over a broad dose range (0.08–5 mg/kg), increased the rates of responding in the fixed‐interval component of the multiple schedule and disrupted patterning of responding within the fixed‐interval, without affecting fixed‐ratio responding even at a dose of 40 mg/kg. The effects of some of the high doses on fixed‐interval responding were still evident one and two days after buprenorphine injection. Doses of buprenorphine which produced increases in fixed‐interval responding were also effective as antagonists of the behavioural depression produced by 40 mg/kg of morphine, and were discriminated as fentanyl‐like by pigeons trained to discriminate between injections of fentanyl and injections of water. These results show that buprenorphine produces marked agonist and antagonist effects over an extremely broad dose range without producing behavioural depressant effects.
Title: Opioid agonist and antagonist behavioural effects of buprenorphine
Description:
The agonist and antagonist effects of a range of bupenorphine doses (0.
08–20 mg/kg) were studied on the responding of pigeons under a multiple fixed‐ratio, fixed‐interval schedule of grain presentation.
Various doses (0.
02–10 mg/kg) of buprenorphine were also tested in pigeons trained to discriminate between injections of 0.
05 mg/kg of fentanyl and injections of distilled water.
Buprenorphine, over a broad dose range (0.
08–5 mg/kg), increased the rates of responding in the fixed‐interval component of the multiple schedule and disrupted patterning of responding within the fixed‐interval, without affecting fixed‐ratio responding even at a dose of 40 mg/kg.
The effects of some of the high doses on fixed‐interval responding were still evident one and two days after buprenorphine injection.
Doses of buprenorphine which produced increases in fixed‐interval responding were also effective as antagonists of the behavioural depression produced by 40 mg/kg of morphine, and were discriminated as fentanyl‐like by pigeons trained to discriminate between injections of fentanyl and injections of water.
These results show that buprenorphine produces marked agonist and antagonist effects over an extremely broad dose range without producing behavioural depressant effects.

Related Results

Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine
Abstract Background: The management of pain in adults with sickle cell disease (SCD) is complex, with the intermingling of both acute vaso-occlusive events and chron...
The Effects of Prenatal Buprenorphine Exposure on the Neurobehavioral Development of the Child
The Effects of Prenatal Buprenorphine Exposure on the Neurobehavioral Development of the Child
Background: Current guidelines for pregnant women with substance use disorder advise prenatal maintenance of opioid agonist therapy with either buprenorphine or methadone. Despite ...
Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl
Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl
ImportanceBuprenorphine treatment of opioid use disorder (OUD) is safe and effective, but opioid withdrawal during treatment initiation is associated with poor retention in care. A...
Long-Term Buprenorphine Treatment for Kratom use Disorder: A Case Series
Long-Term Buprenorphine Treatment for Kratom use Disorder: A Case Series
Background: Opioid agonist therapy with buprenorphine is an effective, evidence-based treatment for opioid use disorder. However, there has been increasing use of alternative subst...
Perioperative pain management and outcomes in patients who discontinued or continued pre-existing buprenorphine therapy
Perioperative pain management and outcomes in patients who discontinued or continued pre-existing buprenorphine therapy
Objective: This study compared opioid utilization and clinical outcomes in surgical patients receiving maintenance buprenorphine therapy who discontinued versus those who continued...
Generalized Restless Body Syndrome: A case of opioid withdrawal- induced restlessness extending beyond the legs
Generalized Restless Body Syndrome: A case of opioid withdrawal- induced restlessness extending beyond the legs
Introduction:Restless leg syndrome (RLS) has been described in those undergoing opioid withdrawal as a factor exacerbating heroin dependence. RLS, however, has not been described a...
Impact of continuous infusions of opioids on discharge opioid prescriptions
Impact of continuous infusions of opioids on discharge opioid prescriptions
Introduction: The 2018 Pain, Agitation/Sedation, Delirium, Immobility, and Sleep guidelines from the Society of Critical Care Medicine recommend opioids as a first-line treatment o...

Back to Top